Altura Medical, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Altura Medical, Inc. - overview
Established
2008
Location
San Clemente, CA, US
Primary Industry
Biotechnology
About
Altura Medical, Inc. develops innovative medical devices that target vascular diseases, focusing on providing minimally invasive solutions for patients suffering from aortic conditions. Founded in 2008 and headquartered in San Clemente, US, Altura Medical specializes in medical devices for vascular treatment. The company was acquired by Lombard Medical, Inc.
in a TRADE SALE valued at USD 23. 00 mn on October 31, 2015, marking a strategic pivot in operations. Altura Medical offers advanced medical devices aimed at treating vascular diseases, particularly aortic pathology. Their product line includes endovascular aortic repair (EVAR), fenestrated endovascular aortic repair (FEVAR), and thoracic endovascular aortic repair (TEVAR) devices, designed for healthcare professionals to perform minimally invasive procedures on patients with vascular conditions.
Altura Medical generates revenue through direct sales and partnerships with healthcare institutions, supplying its medical devices to hospitals and specialized clinics engaged in vascular surgeries. The sales process involves orders from healthcare providers for specific products, with pricing influenced by product type and volume. Following its acquisition, Altura Medical is poised to leverage the resources of Lombard Medical to expand its product offerings and market reach. This includes ongoing development of new vascular treatment devices aimed for market release in the coming years.
The strategic focus will be on penetrating new geographical markets, specifically in Europe and select regions of Asia, by 2025. The funding from the recent TRADE SALE will support these initiatives, enabling enhanced research and development capabilities.
Current Investors
SV Health Investors, Advanced Technology Ventures, New Leaf Venture Partners
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.alturainc.com
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.